

Iris Lansdorp-Vogelaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6911511/publications.pdf>

Version: 2024-02-01

171
papers

12,266
citations

41258

49
h-index

27345

106
g-index

174
all docs

174
docs citations

174
times ranked

11506
citing authors

#	ARTICLE	IF	CITATIONS
1	Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. <i>New England Journal of Medicine</i> , 2012, 366, 687-696.	13.9	2,553
2	Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. <i>Cancer</i> , 2010, 116, 544-573.	2.0	1,691
3	Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2008, 149, 659.	2.0	515
4	Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. <i>Gut</i> , 2019, 68, 1820-1826.	6.1	463
5	Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2595.	3.8	388
6	Population-Based Colonoscopy Screening for Colorectal Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 894.	2.6	258
7	Cost-effectiveness of Colorectal Cancer Screening. <i>Epidemiologic Reviews</i> , 2011, 33, 88-100.	1.3	246
8	Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. <i>Cancer</i> , 2015, 121, 2281-2285.	2.0	180
9	Real-Time Monitoring of Results During First Year of a Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels. <i>Gastroenterology</i> , 2017, 152, 767-775.e2.	0.6	179
10	Effect of Rising Chemotherapy Costs on the Cost Savings of Colorectal Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1412-1422.	3.0	167
11	Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 728-736.	1.1	167
12	The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. <i>Cancer</i> , 2018, 124, 2964-2973.	2.0	157
13	Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. <i>Gut</i> , 2015, 64, 1327-1337.	6.1	150
14	Colorectal Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1998.	3.8	145
15	Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 159, 667.	2.0	135
16	Cost-Effectiveness of Computed Tomographic Colonography Screening for Colorectal Cancer in the Medicare Population. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1238-1252.	3.0	125
17	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. <i>Annals of Internal Medicine</i> , 2014, 161, 104.	2.0	123
18	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. <i>BMJ: British Medical Journal</i> , 2019, 367, l5515.	2.4	122

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness Analysis of a Quantitative Immunochemical Test for Colorectal Cancer Screening. <i>Gastroenterology</i> , 2011, 141, 1648-1655.e1.	0.6	111
20	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020, 158, 1274-1286.e12.	0.6	110
21	Family history and the natural history of colorectal cancer: systematic review. <i>Genetics in Medicine</i> , 2015, 17, 702-712.	1.1	107
22	Colorectal cancer deaths attributable to nonuse of screening in the United States. <i>Annals of Epidemiology</i> , 2015, 25, 208-213.e1.	0.9	102
23	Radiation-Related Cancer Risks From CT Colonography Screening: A Risk-Benefit Analysis. <i>American Journal of Roentgenology</i> , 2011, 196, 816-823.	1.0	101
24	Should Colorectal Cancer Screening Be Considered in Elderly Persons Without Previous Screening?. <i>Annals of Internal Medicine</i> , 2014, 160, 750.	2.0	101
25	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. <i>European Journal of Cancer</i> , 2020, 127, 224-235.	1.3	101
26	Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 304-314.	3.7	99
27	A Systematic Comparison of Microsimulation Models of Colorectal Cancer. <i>Medical Decision Making</i> , 2011, 31, 530-539.	1.2	96
28	Sojourn Time of Preclinical Colorectal Cancer by Sex and Age: Estimates From the German National Screening Colonoscopy Database. <i>American Journal of Epidemiology</i> , 2011, 174, 1140-1146.	1.6	96
29	Rationale and design of the European Polyp Surveillance (EPoS) trials. <i>Endoscopy</i> , 2016, 48, 571-578.	1.0	90
30	Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study. <i>Gut</i> , 2015, 64, 1584-1592.	6.1	79
31	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. <i>BMJ: British Medical Journal</i> , 2019, 367, l5383.	2.4	79
32	State Disparities in Colorectal Cancer Mortality Patterns in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1296-1302.	1.1	76
33	A novel hypothesis on the sensitivity of the fecal occult blood test. <i>Cancer</i> , 2009, 115, 2410-2419.	2.0	74
34	Personalizing Colonoscopy Screening for Elderly Individuals Based on Screening History, Cancer Risk, and Comorbidity Status Could Increase Cost Effectiveness. <i>Gastroenterology</i> , 2015, 149, 1425-1437.	0.6	74
35	Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population. <i>Annals of Internal Medicine</i> , 2010, 153, 368.	2.0	73
36	Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1445-1451.e8.	2.4	73

#	ARTICLE	IF	CITATIONS
37	Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2349.	3.8	72
38	Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. <i>Gut</i> , 2013, 62, 727-734.	6.1	68
39	Individualizing colonoscopy screening by sex and race. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 96-108.e24.	0.5	67
40	Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. <i>Cancer</i> , 2018, 124, 2974-2985.	2.0	66
41	Fecal Occult Blood Testing When Colonoscopy Capacity is Limited. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1741-1751.	3.0	65
42	Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. <i>British Journal of Cancer</i> , 2017, 116, 44-49.	2.9	65
43	At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. <i>International Journal of Cancer</i> , 2009, 124, 1161-1168.	2.3	61
44	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	1.1	61
45	Increasing Incidence of Colorectal Cancer in Adolescents and Young Adults Aged 15-39 Years in Western Australia 1982-2007: Examination of Colonoscopy History. <i>Frontiers in Public Health</i> , 2017, 5, 179.	1.3	60
46	Cost-effectiveness of screening and treating <i>Helicobacter pylori</i> for gastric cancer prevention. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 933-947.	1.0	58
47	The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. <i>Gut</i> , 2015, 64, 1985-1997.	6.1	58
48	Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1933.	3.8	58
49	Cost-effectiveness of colorectal cancer screening - An overview. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 439-449.	1.0	55
50	Effects of cancer screening restart strategies after COVID-19 disruption. <i>British Journal of Cancer</i> , 2021, 124, 1516-1523.	2.9	55
51	Validation of Models Used to Inform Colorectal Cancer Screening Guidelines. <i>Medical Decision Making</i> , 2016, 36, 604-614.	1.2	52
52	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1397-1404.e7.	2.4	51
53	Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. <i>Gut</i> , 2019, 68, 873-881.	6.1	48
54	Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. <i>Journal of the National Cancer Institute</i> , 2021, 113, 154-161.	3.0	46

#	ARTICLE	IF	CITATIONS
55	Clarifying Differences in Natural History between Models of Screening. <i>Medical Decision Making</i> , 2011, 31, 540-549.	1.2	45
56	Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. <i>Gastroenterology</i> , 2017, 153, 1251-1259.e2.	0.6	45
57	Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 60-68.	3.7	42
58	Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs. <i>Radiology</i> , 2018, 287, 901-911.	3.6	40
59	Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. <i>PLoS ONE</i> , 2017, 12, e0172864.	1.1	40
60	Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 747-754.	3.7	40
61	Optimising the expansion of the National Bowel Cancer Screening Program. <i>Medical Journal of Australia</i> , 2014, 201, 456-461.	0.8	39
62	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. <i>PLoS ONE</i> , 2019, 14, e0220234.	1.1	39
63	Adherence to recommendations of Barrett's esophagus surveillance guidelines: a systematic review and meta-analysis. <i>Endoscopy</i> , 2020, 52, 17-28.	1.0	39
64	Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz086.	1.4	39
65	An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. <i>Gastroenterology</i> , 2015, 149, 577-585.e4.	0.6	37
66	Stage distribution of screen-detected colorectal cancers in the Netherlands. <i>Gut</i> , 2018, 67, 1745-1746.	6.1	37
67	Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 158-164.	1.1	36
68	Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 504-512.e11.	2.4	36
69	Fecal immunochemical test-based colorectal cancer screening: The gender dilemma. <i>United European Gastroenterology Journal</i> , 2017, 5, 448-454.	1.6	35
70	Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1464-1471.e4.	2.4	34
71	How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?. <i>Cancer</i> , 2011, 117, 4166-4174.	2.0	33
72	Comparative Economic Evaluation of Data from the ACRIN National CT Colonography Trial with Three Cancer Intervention and Surveillance Modeling Network Microsimulations. <i>Radiology</i> , 2011, 261, 487-498.	3.6	33

#	ARTICLE	IF	CITATIONS
73	The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic. <i>Preventive Medicine</i> , 2021, 151, 106643.	1.6	32
74	Screening for gastric cancer in Western countries. <i>Gut</i> , 2016, 65, 543-544.	6.1	30
75	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018, 142, 741-746.	2.3	29
76	Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1493-1500.	2.4	29
77	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening. <i>International Journal of Cancer</i> , 2020, 147, 1098-1106.	2.3	29
78	Productivity Savings from Colorectal Cancer Prevention and Control Strategies. <i>American Journal of Preventive Medicine</i> , 2011, 41, e5-e14.	1.6	28
79	Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 397-404.e2.	0.5	28
80	Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. <i>European Journal of Cancer</i> , 2022, 161, 38-43.	1.3	28
81	Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 622-631.	3.7	27
82	Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. <i>Gastroenterology</i> , 2018, 154, 105-116.e20.	0.6	26
83	The Appropriateness of More Intensive Colonoscopy Screening Than Recommended in Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , 2014, 174, 1568.	2.6	25
84	Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era. <i>Gastroenterology</i> , 2020, 159, 1998-2003.	0.6	25
85	Risk-stratified strategies in population screening for colorectal cancer. <i>International Journal of Cancer</i> , 2022, 150, 397-405.	2.3	25
86	Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. <i>Gut</i> , 2017, 66, 118-123.	6.1	24
87	Nonbleeding adenomas: Evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectiveness—a modeling study. <i>Cancer</i> , 2016, 122, 1680-1688.	2.0	22
88	Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. <i>BMC Cancer</i> , 2018, 18, 464.	1.1	22
89	Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 10-21.	1.1	22
90	Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. <i>Gastroenterology</i> , 2018, 154, 556-567.e18.	0.6	21

#	ARTICLE	IF	CITATIONS
91	Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1771-1777.	2.4	20
92	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1471-1474.	2.4	20
93	Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. <i>Journal of Medical Screening</i> , 2020, 27, 68-76.	1.1	19
94	Calculation of Stop Ages for Colorectal Cancer Screening Based on Comorbidities and Screening History. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 547-555.	2.4	19
95	State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences. <i>Cancer</i> , 2015, 121, 3676-3683.	2.0	18
96	Assessment of a cancer screening program. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 979-985.	1.0	18
97	Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?. <i>Gut</i> , 2017, 66, 1262-1267.	6.1	18
98	High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas. <i>Annals of Internal Medicine</i> , 2019, 171, 612.	2.0	18
99	Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101735.	1.0	18
100	Development of new noninvasive tests for colorectal cancer screening: The relevance of information on adenoma detection. <i>International Journal of Cancer</i> , 2015, 136, 2864-2874.	2.3	17
101	Optimal Colorectal Cancer Screening in States' Low-Income, Uninsured Populations-The Case of South Carolina. <i>Health Services Research</i> , 2015, 50, 768-789.	1.0	16
102	Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries. <i>Health Affairs</i> , 2017, 36, 2151-2159.	2.5	16
103	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2018, 155, 1392-1399.e5.	0.6	16
104	A cost-effectiveness analysis of online, radio and print tobacco control advertisements targeting 25-39 year old males. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 270-274.	0.8	15
105	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1961-1969.	2.4	15
106	Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study. <i>Journal of the National Cancer Institute</i> , 2022, , .	3.0	15
107	Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1328-1336.	1.1	14
108	Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 307-312.	1.3	13

#	ARTICLE	IF	CITATIONS
109	Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. <i>Medical Care</i> , 2015, 53, 630-638.	1.1	12
110	Developing a score chart to improve risk stratification of patients with colorectal adenoma. <i>Endoscopy</i> , 2016, 48, 563-570.	1.0	12
111	Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1418-1425.	2.4	12
112	Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1737-1744.	1.4	11
113	Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. <i>Health Policy</i> , 2018, 122, 1206-1211.	1.4	11
114	Yield of Surveillance Colonoscopies 1 Year After Curative Surgical Colorectal Cancer Resections. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2285-2293.	2.4	11
115	Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary. <i>Journal of Medical Screening</i> , 2021, 28, 268-276.	1.1	11
116	The impact of information about different absolute benefits and harms on intention to participate in colorectal cancer screening: A think-aloud study and online randomised experiment. <i>PLoS ONE</i> , 2021, 16, e0246991.	1.1	11
117	Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing. <i>PLoS ONE</i> , 2022, 17, e0264067.	1.1	11
118	Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. <i>Medical Decision Making</i> , 2018, 38, 917-929.	1.2	10
119	Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 111-118.	3.7	10
120	Measures of longitudinal adherence to fecal-based colorectal cancer screening: Literature review and recommended approaches. <i>International Journal of Cancer</i> , 2021, 149, 316-326.	2.3	10
121	Calibrating Parameters for Microsimulation Disease Models. <i>Medical Decision Making</i> , 2016, 36, 652-665.	1.2	9
122	Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 208.	0.5	9
123	The impact of stratifying by family history in colorectal cancer screening programs. <i>International Journal of Cancer</i> , 2015, 137, 1119-1127.	2.3	8
124	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. <i>BMC Cancer</i> , 2017, 17, 112.	1.1	8
125	Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2760-2767.e12.	2.4	8
126	Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. <i>International Journal of Cancer</i> , 2021, 149, 337-346.	2.3	8

#	ARTICLE	IF	CITATIONS
127	Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. <i>Gut</i> , 2023, 72, 101-108.	6.1	8
128	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. <i>PLoS ONE</i> , 2018, 13, e0202924.	1.1	7
129	Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program. <i>Clinical Chemistry</i> , 2019, 65, 419-426.	1.5	7
130	Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial. <i>Medical Decision Making</i> , 2020, 40, 1034-1040.	1.2	7
131	The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. <i>Preventive Medicine Reports</i> , 2021, 22, 101392.	0.8	7
132	Optimising colorectal cancer screening in Shanghai, China: a modelling study. <i>BMJ Open</i> , 2022, 12, e048156.	0.8	7
133	The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. <i>Medical Decision Making</i> , 2015, 35, 726-733.	1.2	6
134	Cost effectiveness of surveillance for GI cancers. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 879-891.	1.0	6
135	Impact of adenoma detection on the benefit of faecal testing vs colonoscopy for colorectal cancer. <i>International Journal of Cancer</i> , 2017, 141, 2359-2367.	2.3	6
136	Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland. <i>Preventive Medicine</i> , 2022, 157, 106990.	1.6	6
137	COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies. <i>Journal of Cancer Policy</i> , 2022, 32, 100328.	0.6	6
138	Evaluation of New Technologies for Cancer Control Based on Population Trends in Disease Incidence and Mortality. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 117-123.	0.9	5
139	Utilization of Surveillance after Polypectomy in the Medicare Population – A Cohort Study. <i>PLoS ONE</i> , 2014, 9, e110937.	1.1	5
140	Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. <i>Journal of Clinical Medicine</i> , 2020, 9, 190.	1.0	5
141	Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening. <i>Value in Health</i> , 2021, 24, 353-360.	0.1	5
142	Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline "Noncompliant Women. <i>JAMA Oncology</i> , 2021, 7, 885.	3.4	5
143	Colorectal cancer screening in Australia. <i>Lancet Public Health</i> , The, 2017, 2, e304-e305.	4.7	4
144	Colorectal Cancer Screening in Young Adults. <i>Annals of Internal Medicine</i> , 2021, 174, 1039-1040.	2.0	4

#	ARTICLE	IF	CITATIONS
145	Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. PLoS ONE, 2021, 16, e0253893.	1.1	4
146	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. MDM Policy and Practice, 2021, 6, 238146832098497.	0.5	4
147	Integrating personalised genomics into risk stratification models of population screening for colorectal cancer. Australian and New Zealand Journal of Public Health, 2017, 41, 3-4.	0.8	3
148	Optimizing Patient Risk Stratification for Colonoscopy Screening and Surveillance of Colorectal Cancer: The Role for Linked Data. Frontiers in Public Health, 2017, 5, 234.	1.3	3
149	Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals?. MDM Policy and Practice, 2022, 7, 238146832210970.	0.5	3
150	Different modalities for colorectal cancer screening: experiences in The Netherlands so far. Colorectal Cancer, 2016, 5, 9-19.	0.8	2
151	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. BMC Gastroenterology, 2021, 21, 67.	0.8	2
152	Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study. Cancer Medicine, 2021, 10, 6835-6844.	1.3	2
153	Comparing Colorectal Cancer Screening Outcomes in the International Cancer Screening Network: A Consortium Proposal. Gastroenterology, 2022, 162, 668-674.	0.6	2
154	Urban density differences in colorectal cancer screening participation and screening yield in The Netherlands. Preventive Medicine Reports, 2022, 27, 101791.	0.8	2
155	ADENOMA DETECTION RATE AND RISK OF INTERVAL POST-COLONOSCOPY COLORECTAL CANCER IN FIT-BASED SCREENING. Gastrointestinal Endoscopy, 2022, 95, AB82-AB83.	0.5	2
156	Cost-effectiveness analysis of colorectal cancer screening in Shanghai, China: A modelling study. Preventive Medicine Reports, 2022, 29, 101891.	0.8	2
157	The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management. American Journal of Gastroenterology, 2020, 115, 1026-1035.	0.2	1
158	Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. American Journal of Gastroenterology, 2021, 116, 1730-1733.	0.2	1
159	An Evolutionary Algorithm to Personalize Stool-Based Colorectal Cancer Screening. Frontiers in Physiology, 2021, 12, 718276.	1.3	1
160	Response to the letter to the editor by Hassan <i>et al.</i> : The diminutive lesion <i>versus</i> the advanced adenoma: Which is the real target of CT colonography screening?. International Journal of Cancer, 2009, 125, 1239-1240.	2.3	0
161	351: Post-Polypectomy Surveillance Practice of Adenoma Patients - Considerable Room for Improvement. Gastrointestinal Endoscopy, 2010, 71, AB115-AB116.	0.5	0
162	M1403: Perforation and Mortality of Colonoscopy - A Systematic Review. Gastrointestinal Endoscopy, 2010, 71, AB211-AB212.	0.5	0

#	ARTICLE	IF	CITATIONS
163	Using Patient Preferences to Determine Noninferiority Margins in Trials. JAMA - Journal of the American Medical Association, 2019, 322, 2137.	3.8	0
164	Interpretation and adherence to the updated risk-stratified guideline for colonoscopy surveillance after polypectomy – a nationwide survey. Endoscopy International Open, 2020, 08, E1405-E1413.	0.9	0
165	Intensity of Surveillance for Patients With Colorectal Adenomas. Annals of Internal Medicine, 2020, 172, 442.	2.0	0
166	The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands.. Journal of Clinical Oncology, 2021, 39, 3531-3531.	0.8	0
167	Colonoscopy and Its Complications are Inseparable of FIT-Based Screening. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
168	Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner. Alimentary Pharmacology and Therapeutics, 2021, 53, 1118-1125.	1.9	0
169	A restricted look at CRC screening: not considering annual stool testing as an option. American Journal of Managed Care, 2016, 22, e270-4.	0.8	0
170	A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance. PLoS ONE, 2022, 17, e0267503.	1.1	0
171	Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic. PLoS ONE, 2022, 17, e0270223.	1.1	0